Jennison Associates Portfolio holdings
Jennison Associates, founded in 1969 and headquartered in New York City, is a global investment management firm managing over $194 billion in assets as of late 2024, specializing in active equity and fixed-income strategies. A subsidiary of PGIM, the asset management arm of Prudential Financial, Jennison serves a diverse client base—including institutions, sub-advisory clients, public plans, endowments, and corporations—with a focus on fundamental research, bottom-up portfolio construction, and high-conviction investing. Known for its equity expertise across styles, geographies, and market capitalizations, as well as investment-grade fixed-income offerings, the firm employs seasoned portfolio managers averaging 29 years of industry experience and 16 years with Jennison. With additional offices in Boston and a culture emphasizing intellectual rigor and long-term client outcomes, Jennison has built a reputation for excellence and stability in the investment management industry.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Perrigo
PRGO
|
+$672M |
| 2 |
Merck
MRK
|
+$608M |
| 3 |
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
|
+$384M |
| 4 |
Las Vegas Sands
LVS
|
+$378M |
| 5 |
TFCFA
Twenty-First Century Fox, Inc. Class A
TFCFA
|
+$303M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Ralph Lauren
RL
|
+$518M |
| 2 |
eBay
EBAY
|
+$474M |
| 3 |
Estee Lauder
EL
|
+$435M |
| 4 |
Goldman Sachs
GS
|
+$323M |
| 5 |
TechnipFMC
FTI
|
+$304M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 20.03% |
| 2 | Consumer Discretionary | 13.85% |
| 3 | Communication Services | 11.23% |
| 4 | Technology | 10.46% |
| 5 | Energy | 9.31% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
451
Madrigal Pharmaceuticals
MDGL
$12.6B
| $17.2M | 0.02% |
113,724
+563
| +0.5% | +$111K |
|
452
NETSCOUT
NTCT
$2.83B
| $17.1M | 0.02% |
455,807
-85,940
| -16% | -$3.03M |
|
|
KIN
453
DELISTED
Kindred Biosciences, Inc.
KIN
| $16.8M | 0.02% |
908,190
+6,416
| +0.7% | +$122K |
|
|
VITC
454
DELISTED
VITACOST COM INC COM STK (DE)
VITC
| $16.8M | 0.02% |
2,370,851
-255,544
| -10% | -$1.6M |
|
455
Benchmark Electronics
BHE
$2.66B
| $16.8M | 0.02% |
+740,369
| New | +$17.3M |
|
|
BLUE
456
DELISTED
bluebird bio
BLUE
| $16.6M | 0.02% |
56,395
-6,101
| -10% | -$1.85M |
|
|
DSCI
457
DELISTED
Derma Sciences, Inc. Common Stock (DE)
DSCI
| $16.1M | 0.02% |
1,271,921
+3,449
| +0.3% | +$44.6K |
|
458
Chefs' Warehouse
CHEF
$4.31B
| $16.1M | 0.02% |
751,444
-39,685
| -5% | -$954K |
|
459
Kinross Gold
KGC
$27.7B
| $15.9M | 0.02% |
3,847,152
-3,535,371
| -48% | -$17M |
|
|
FCSC
460
DELISTED
Fibrocell Science Inc.
FCSC
| $15.5M | 0.01% |
197,290
+1,091
| +0.6% | +$84.6K |
|
461
Liquidity Services
LQDT
$1.2B
| $15.4M | 0.01% |
+589,724
| New | +$14.3M |
|
|
CMRX
462
DELISTED
Chimerix, Inc.
CMRX
| $15.1M | 0.01% |
661,287
+3,729
| +0.6% | +$75.2K |
|
|
I
463
DELISTED
INTELSAT S. A.
I
| $14.7M | 0.01% |
787,064
-530,606
| -40% | -$10.8M |
|
|
CSII
464
DELISTED
Cardiovascular Systems, Inc.
CSII
| $14.7M | 0.01% |
463,451
+110,434
| +31% | +$3.65M |
|
465
McEwen Inc
MUX
$1B
| $14.5M | 0.01% |
612,083
-20,650
| -3% | -$556K |
|
|
SC
466
DELISTED
SANTANDER CONSUMER USA HOLDINGS INC
SC
| $14.4M | 0.01% |
+597,997
| New | +$14.8M |
|
|
RALY
467
DELISTED
RALLY SOFTWARE DEV CORP
RALY
| $14.1M | 0.01% |
1,056,061
+62,802
| +6% | +$1.25M |
|
468
Douglas Emmett
DEI
$2.05B
| $14M | 0.01% |
517,592
+23,123
| +5% | +$598K |
|
|
ALXN
469
PUT
DELISTED
Alexion Pharmaceuticals
ALXN
| $14M | 0.01% |
+92,000
| New | +$14.6M |
|
|
TFM
470
DELISTED
THE FRESH MARKET, INC COM STK
TFM
| $14M | 0.01% |
415,591
-1,363,525
| -77% | -$48M |
|
471
Ultragenyx Pharmaceutical
RARE
$2.46B
| $13.8M | 0.01% |
+283,220
| New | +$14.6M |
|
|
WBMD
472
DELISTED
WebMD Health Corp.
WBMD
| $13.7M | 0.01% |
331,438
-596,218
| -64% | -$26.9M |
|
|
I.PRA
473
DELISTED
INTELSAT S A MANDATORY CONV JR NON VTG PFD SHS (LUX)
I.PRA
| $13M | 0.01% |
+242,300
| New | +$13.3M |
|
474
Arrowhead Research
ARWR
$12.1B
| $12.8M | 0.01% |
+776,746
| New | +$13.6M |
|
|
MLU
475
DELISTED
METLIFE, INC. COM EQUITY UNIT
MLU
| $12.7M | 0.01% |
413,000
| – | – |
|
Similar funds
Jennison Associates's Q1 2014 Portfolio in Review
As of Q1 2014, Jennison Associates held 826 positions worth $105B, up 2.6% from $102B the previous quarter. Its ten largest holdings account for 18% of the portfolio.
Jennison Associates's Q1 2014 filing shows 122 new, 275 increased, 321 reduced and 94 closed positions. Its largest new stake was Perrigo: 4,257,843 shares worth $659M. The largest sale was Ralph Lauren, an estimated $518M.
By sector, the portfolio is most concentrated in Healthcare at 20% of assets, up from 18% a quarter earlier, followed by Consumer Discretionary and Communication Services.
- Jennison Associates's largest Q1 2014 buy was Perrigo: 4,257,843 shares worth $659M.
- Jennison Associates added most to Merck in Q1 2014, an estimated $608M increase.
- Jennison Associates's biggest Q1 2014 reduction was Estee Lauder, cutting an estimated $435M.
- Jennison Associates fully exited Ralph Lauren in Q1 2014, selling an estimated $518M.
- Jennison Associates's ten largest holdings make up 18% of its $105B portfolio in Q1 2014.
- Jennison Associates opened 122 new positions and closed 94 in Q1 2014.
- Jennison Associates's portfolio value rose 2.6% quarter-over-quarter to $105B.
Based on Jennison Associates's 13F filing for Q1 2014, filed 7 May 2014.